African Trypanosomiasis - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463995 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

African Trypanosomiasis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide African Trypanosomiasis - Pipeline Review, H2 2019, provides an overview of the African Trypanosomiasis (Infectious Disease) pipeline landscape.

African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness. Treatment includes anti-protozoal agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide African Trypanosomiasis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The African Trypanosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.

African Trypanosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of African Trypanosomiasis (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in African Trypanosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates African Trypanosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for African Trypanosomiasis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for African Trypanosomiasis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding African Trypanosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

African Trypanosomiasis - Overview

African Trypanosomiasis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

African Trypanosomiasis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

African Trypanosomiasis - Companies Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd

Novartis AG

Pfizer Inc

Sanofi

Scynexis Inc

African Trypanosomiasis - Drug Profiles

acoziborole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBL-0137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DDD-100097 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexinidazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNF-6702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDL-73811 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melarsoprol hydroxypropylbetadex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Sleeping Sickness - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCYX-1330682 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCYX-1608210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Protozoal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Sleeping Sickness - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Rhodesain for African Trypanosomiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Variant Surface Glycoprotein for African Trypanosomiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

African Trypanosomiasis - Dormant Projects

African Trypanosomiasis - Discontinued Products

African Trypanosomiasis - Product Development Milestones

Featured News & Press Releases

Nov 16, 2018: Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness

Nov 16, 2018: CHMP recommends first oral-only treatment for sleeping sickness

Jan 31, 2018: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment

Nov 04, 2017: Phase II/III Studies Show High Efficacy and Safety of Fexinidazole, the First Oral Treatment for Sleeping Sickness

Aug 30, 2016: UGA researchers discover a drug for a tropical disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463995 | GMDHC11443IDB

Number of Pages

59

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

African Trypanosomiasis - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.